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in the formation of lymphocyte follicles in the lungs,
more common in advanced disease, and dominated by
B-lymphocytes. Cells more commonly described in
asthma pathogenesis also seem to be involved in COPD.
Eosinophils are more common in central airways
biopsies in smokers than in non-smokers, and these cells
are more commonly seen in the mucosa during COPD
exacerbations. Mast cells have also been seen in central
airways in smokers, and recently their occurrence in
peripheral airways is under investigation.
The issue of systemic inflammation is also under
intensive research currently, with certain emphasis on
comorbid conditions in COPD. Of special interest is the
coupling between COPD and cardiovascular disorders,
mostly related to atherosclerosis. Very recent results
from our group indicate that vulnerability for systemic
inflammatory reactions could be a risk factor for the
development of COPD, as elevation of acute phase
proteins in subjects clearly increased the risk of being
hospitalised decades after the measurement of the
acute phase proteins (Engstrom G et al. Thorax 2009, e-
publication).
The concept of inflammation in COPD is under
development, and hopefully this knowledge will in the
future increase the treatment possibilities in COPD.
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Remodelling can be defined as alteration of tissue archi-
tecture. This dynamic process involves a number of cells
including structural cells and occurs both during normal
organ development and in response to injury. Chronic
inflammation and remodelling are linked, and may
result difficulties in maintaining normal tissue function.
Diagnosis of asthma and COPD is based upon limitation
of expiratory airflow. The pathophysiological correlates
to this lung function impairment are complex but are
associated with development of structural changes in the
airways and lung parenchyma. In addition, the preceding
inflammation differs, both between the two diseases,
but also between various airway and lung compartments
and may also differ from one patient to another. Both
asthma and COPD are heterogeneous disorders including
various phenotypes and there is a considerable overlap
between two the diseases.
In asthma, airways obstruction is thought to be
predominately located in the large airways. Thus,
epithelial desquamation, subepithelial fibrosis and
increased smooth muscle mass are seen and may,
together with inflammatory infiltration lead to airway
narrowing. Recent studies have, however, indicated that
inflammation and probably also remodelling in asthma
are also present in other compartments in the lung, such
as the small airways.
In the large airways in COPD, there is an increased
amount of goblet cells and glands which may result in
the clinical picture of chronic bronchitis. However, the
large airways are not the major site of the airways
obstruction in COPD. Instead, structural changes in the
small airways and lung parenchyma are the main
correlates for the limitation of expiratory airflow. In the
small airways, peribronchiolar fibrosis (bronchiolitis),
are seen and the wall thickness in COPD have been
found to correlate to forced expiratory volume in one
second (FEV1). Bronchiolitis in COPD may be accom-
panied by emphysema, i.e. destruction of alveolar walls
resulting in a decreased gas exchange area.
Thus, localization of the structural changes differs
between the two diseases suggesting that they should
be treated differently. Currently, the main pharmaco-
logical treatment of asthma and COPD are broncho-
dilators and glucocorticoids. It seems that the more
distal in the lung the remodeling occur, the more
irreversible it is to this available treatment.
In COPD and severe asthma, available pharmaco-
therapy has not proven to restore lung function
impairment. It is therefore increasingly recognized that
research aiming to explore mechanisms of airway
remodeling should be encouraged. This may lead to
development of new therapeutic strategies in order to
interfere with the biology of structural cells, hopefully
resulting in a possible restoration of lung architecture.
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Chronic obstructive pulmonary disease (COPD) is
defined by chronic airflow limitation associated with an
abnormal pulmonary inflammatory response of the lungs
to inhaled particles and gases, usually cigarette smoke.
However, it is now recognised that in addition to the
effects in the lungs COPD, like many chronic diseases
has systemic consequences which result in comorbities
which influence both morbidity and mortality.
The cause of these systemic effects is not well
understood but is thought to result from a systemic
inflammatory response, which produces the systemic
effects such as weight loss, muscle wasting, and
increased risk of cardiovascular disease, metabolic
syndrome, cancer and osteoporosis. The ageing process
is characterised by progressive, generalised impairment
of function resulting in an increasing vulnerability to
environmental challenge and an increased risk of
disease. Accelerated ageing is a further hypothesis
which could account for both the local lung and
systemic effects of COPD.
The diagnosis and assessment of severity of COPD
may be greatly affected by the presence of co morbid
conditions and it may be that in addition to lung
function measurements, assessment of cardiovascular
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and metabolic functions, and circulating inflammatory
markers might help to better characterise these
patients.
Diagnosis of COPD
J. Vestbo
Hvidovre Hospital & University of Copenhagen, DK, and
Wythenshawe Hospital & University of Manchester, UK
E-mail address: Jorgen.Vestbo@manchester.ac.uk
The diagnosis of COPD relies on the demonstration of
fixed airflow limitation in the absence of less frequent
diseases causing airways obstruction. Guidelines have
for decades used the ratio of FEV1/VC or FEV1/FVC as
the measurements of choice; this has rarely been the
cause of debate whereas the cut-off values for the ratio
have been intensely debated. The fixed ratio of 0.7
causes under-diagnosis of COPD in younger adults and
over-diagnosis in the elderly whereas the use of lower
limit of normal presumes that less than 5% of elderly
asymptomatic smokers can have COPD as ‘normality’ is
defined according to statistics only.
More importantly, however, the current diagnostic
guidance does not take into account that we define
COPD as 1) a disease characterised by an abnormal
inflammatory response, 2) a disease with a frequently
occurring extrapulmonary component – and 3) that we
know that one of the main subtypes of COPD,
emphysema, often does not lead to airflow limitation in
its earliest stages. We will need to decide whether we
want to keep our simple diagnostic criteria and sub-
sequently try to describe the individual patient’s
features by “sub-grouping” COPD or whether our
diagnostic criteria should mirror how we define the
disease.
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The most recent definition of COPD clearly states that
the disease is both preventable and treatable. The
knowledge on interventions that may improve the
clinical course of COPD is constantly expanding and the
COPD patients of today are facing a totally different
approach from the health professionals compared to the
situation 20 years ago. This means that the clinical
course of the disease need no longer result in a con-
tinuing decline of lung function, repeated exacerbations
and development of respiratory failure. Whereas
smoking cessation in the early stage of COPD and long
term oxygen treatment in the end-stage disease were in
the past thought to be the only two modalities affecting
the long term clinical course of the disease, it is now
documented that also pharmacological treatment with
long acting antimuscarinic agents, long acting beta-2-
agonists and inhaled corticosteroids, rehabilitation
comprising physical exercise and immunisation against
influenza affects the long term prognosis and improves
the health related quality of life of the patients. Also
the treatment of acute exacerbations with non-invasive
ventilation has revolutionised the clinical practice by
reducing both mortality and the need for intubation.
In order to implement these options with success, the
timing of intervention is essential. In this context the
more widespread use of spirometry, assessment of the
severity of dyspnea and identification of patients with
repeated exacerbation is mandatory. The pulmonary
community has a major obligation in assuring that the
knowledge from the successful controlled trials will be
implemented in the clinical practice.
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The usefulness of exhaled nitric oxide (eNO) measure-
ment is still controversial in chronic obstructive pul-
monary disease (COPD). However, modelling measure-
ments of eNO from multiple flows may provide measures
of parenchymal and airway inflammation and could
potentially be used to monitor inflammation in COPD. In
my PhD study I will investigate any possible correlation
between local inflammation and systemic inflammation
in COPD patients and relate it to presence/development
of cardiac disease.
Ninety one (91) COPD patients recruited in the
ECLIPSE study with FEV1 ranging from 17-77% have been
seen every three months in the first year and every six
months in the following eighteen month period. I aim to
use two compartment nonlinear modelling of multiple
flow rates eNO at 10, 30, 50, 100 and 200 mL·s–1, but
currently only raw eNOs are available and eNO50 is used
to indicate airway inflammation. The following
biochemical markers of inflammation in serum are used:
IL-6, IL-8, TNFα, Clara cell secretory protein-16 (CC-16),
and Surfactant Protein D (SPD).
Neither eNO50 nor any of the systemic markers varied
according to age, gender or GOLD stage except IL6 which
increased by age. There was no correlation between
eNO50 and any of the systemic markers. There was an
association between TNFα and PARC (r=.26, p=.01) but no
other inter-relations between systemic markers. IL-6 was
significantly elevated in subjects with ischemic heart
disease (7.27 vs 2.13 pg/mL, p<.001) as was CC-16 (6.17
vs. 4.86 ng/mL, p=.03), none of the others markers were
related to heart disease at baseline.
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